Join

Compare · ELV vs GTH

ELV vs GTH

Side-by-side comparison of Elevance Health Inc. (ELV) and Genetron Holdings Limited (GTH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ELV and GTH operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ELV is the larger of the two at $90.81B, about 289.5x GTH ($313.7M).
  • ELV has hit the wire 3 times in the past 4 weeks while GTH has been quiet.
  • ELV has more recent analyst coverage (23 ratings vs 0 for GTH).
MetricELVGTH
Company
Elevance Health Inc.
Genetron Holdings Limited
Price
$418.31+0.63%
$4.02+0.00%
Market cap
$90.81B
$313.7M
1M return
+12.19%
-
1Y return
+7.35%
-
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
3
0
Recent ratings
23
0
ELV

Elevance Health Inc.

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

GTH

Genetron Holdings Limited

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Latest ELV

Latest GTH